Brought to you by 
Public offering nets $304.7mm for Guardant Health
28 May 2019
Executive Summary
Precision oncology firm Guardant Health Inc. netted $304.7mm through the public offering of 4.5mm common shares at $71. The company markets two liquid biopsy products--Guardant360 and GuardantOMNI--which are used in treatment selection and drug development settings, respectively, and is also developing assays for cancer recurrence detection and early disease screening.
Deal Industry
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Public offering nets $304.7mm for Guardant Health
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice